← back to search

LeAnne T. Bloedon

Esperion Therapeutics (United States) · US
Area of research
Surgery · Cancer Research
Research interest
Research interests include Lipoproteins and Cardiovascular Health, Cancer, Lipids, and Metabolism, Diabetes, Cardiovascular Risks, and Lipoproteins, and Cholesterol and Lipid Metabolism.
h-index
28
citations
7,045
works
82
NIH funding
primary concept
Medicine
email

Recent publications

Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients
New England Journal of Medicine 2023cited by 843position: middledoi
Efficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trials
Journal of clinical lipidology 2022cited by 37position: middledoi
Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol
New England Journal of Medicine 2019cited by 787position: middledoi
Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance
Journal of the American Heart Association 2019cited by 426position: middledoi
Oral Apolipoprotein A‐I Mimetic D‐4F Lowers HDL‐Inflammatory Index in High‐Risk Patients: A First‐in‐Human Multiple‐Dose, Randomized Controlled Trial
Clinical and Translational Science 2017cited by 61position: middledoi
The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia – A post-hoc analysis of a Phase 3, single-arm, open-label trial
Atherosclerosis 2015cited by 45position: middledoi
Abstract 12450: Long-Term Efficacy and Safety of Lomitapide for the Treatment of Homozygous Familial Hypercholesterolemia: Results of the Phase 3 Extension Trial
Circulation 2015cited by 4position: middledoi
Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study
The Lancet 2012cited by 736position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Daniel Gaudet · Thrombolysis in Myocardial Infarction Study Group4 papers (2012–2019)Daniel J. Rader · RWTH Aachen University4 papers (2012–2017)Dirk Blom · South African Medical Research Council3 papers (2012–2015)Claudia Stefanutti · Amgen (United States)3 papers (2012–2015) · 3 papers (2012–2015)Robert A. Hegele · Western University3 papers (2012–2015)Giovanni Battista Vigna · University of Ferrara3 papers (2012–2015)Emma A. Meagher · Translational Therapeutics (United States)3 papers (2012–2015)Marina Cuchel · World Heart Federation3 papers (2012–2015)Maurizio Averna · European Atherosclerosis Society3 papers (2012–2015)Alberico L. Catapano · Novo Nordisk (United Kingdom)2 papers (2019–2022) · 2 papers (2012–2015)Prediman K. Shah · Cedars-Sinai Medical Center2 papers (2012–2015)Kausik K. Ray · Imperial College London2 papers (2019–2022)G.B. John Mancini · Ospedale Generale Regionale Francesco Miulli2 papers (2019–2022)Lulu Ren Sterling · Amgen (United States)2 papers (2019–2019)A. David Marais · University of Cape Town2 papers (2012–2015)Maciej Banach · University of Southampton2 papers (2019–2022)Christie M. Ballantyne · New York University2 papers (2019–2022)Harold Bays · Louisville Metabolic and Atherosclerosis Research Center2 papers (2019–2022)